Literature DB >> 15492230

Inhibitor of apoptosis proteins: translating basic knowledge into clinical practice.

Aaron D Schimmer1.   

Abstract

The inhibitor of apoptosis proteins (IAPs) are a family of antiapoptotic proteins that bind and inhibit caspases 3, 7, and/or 9, but not caspase 8. Growing evidence also indicates that IAPs also modulate cell division, cell cycle progression, and signal transduction pathways. As our basic understanding of IAPs has increased, the knowledge is being translated into clinically useful applications in the diagnosis and treatment of malignancy. For example, IAPs such as survivin are being investigated as diagnostic markers for the presence of occult malignancy. In addition, IAP overexpression is a poor prognostic marker in a variety of solid tumors and hematologic malignancies. Finally, IAPs are attractive therapeutic targets, and efforts are under way to develop antisense and chemical IAP inhibitors that may be useful for the treatment of a variety of malignancies. For all of these potential clinical applications, however, the challenge remains to incorporate these findings into actual clinical practice.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15492230     DOI: 10.1158/0008-5472.CAN-04-1918

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  136 in total

1.  Targeting X-linked inhibitor of apoptosis protein inhibits pancreatic cancer cell growth through p-Akt depletion.

Authors:  Chun Jiang; Xiao-Ping Yi; Hong Shen; Yi-Xiong Li
Journal:  World J Gastroenterol       Date:  2012-06-21       Impact factor: 5.742

Review 2.  Novel therapeutic targets for pancreatic cancer.

Authors:  Shing-Chun Tang; Yang-Chao Chen
Journal:  World J Gastroenterol       Date:  2014-08-21       Impact factor: 5.742

Review 3.  Immune surveillance in melanoma: From immune attack to melanoma escape and even counterattack.

Authors:  Fade Mahmoud; Bradley Shields; Issam Makhoul; Nathan Avaritt; Henry K Wong; Laura F Hutchins; Sara Shalin; Alan J Tackett
Journal:  Cancer Biol Ther       Date:  2017-05-17       Impact factor: 4.742

4.  cIAP2 represses IKKα/β-mediated activation of MDM2 to prevent p53 degradation.

Authors:  Rosanna Lau; Min Ying Niu; M A Christine Pratt
Journal:  Cell Cycle       Date:  2012-10-03       Impact factor: 4.534

5.  Discovery of Dual Inhibitors of MDM2 and XIAP for Cancer Treatment.

Authors:  Lubing Gu; Hailong Zhang; Tao Liu; Sheng Zhou; Yuhong Du; Jing Xiong; Sha Yi; Cheng-Kui Qu; Haian Fu; Muxiang Zhou
Journal:  Cancer Cell       Date:  2016-09-22       Impact factor: 31.743

Review 6.  Survivin as a novel target protein for reducing the proliferation of cancer cells.

Authors:  Dongyu Li; Chenghao Hu; Huibin Li
Journal:  Biomed Rep       Date:  2018-03-13

7.  The tumor gene survivin is highly expressed in adult renal tubular cells: implications for a pathophysiological role in the kidney.

Authors:  Philipp Lechler; Xiaoqing Wu; Wanja Bernhardt; Valentina Campean; Susanne Gastiger; Thomas Hackenbeck; Bernd Klanke; Alexander Weidemann; Christina Warnecke; Kerstin Amann; Dirk Engehausen; Carsten Willam; Kai-Uwe Eckardt; Franz Rödel; Michael Sean Wiesener
Journal:  Am J Pathol       Date:  2007-11       Impact factor: 4.307

Review 8.  Dysregulation of apoptotic signaling in cancer: molecular mechanisms and therapeutic opportunities.

Authors:  Jessica Plati; Octavian Bucur; Roya Khosravi-Far
Journal:  J Cell Biochem       Date:  2008-07-01       Impact factor: 4.429

Review 9.  Urothelial carcinoma: stem cells on the edge.

Authors:  William D Brandt; William Matsui; Jonathan E Rosenberg; Xiaobing He; Shizhang Ling; Edward M Schaeffer; David M Berman
Journal:  Cancer Metastasis Rev       Date:  2009-12       Impact factor: 9.264

10.  PAK1 is a novel MEK-independent raf target controlling expression of the IAP survivin in M-CSF-mediated osteoclast survival.

Authors:  Elizabeth W Bradley; Ming M Ruan; Merry J Oursler
Journal:  J Cell Physiol       Date:  2008-12       Impact factor: 6.384

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.